IP Library › Granted Patent US 12692257

Granted Patent B2

US 12692257 · App. 17/926,533 · Granted Jul 28, 2026

2,4,6-tri-substituted pyrimidine compounds as ATR kinase inhibitors

Inventors: Yanping Zhao (Beijing, CN); Bin Liu (Beijing, CN); Yuanyuan Jiang (Beijing, CN); Weiting Zhong (Beijing, CN); Huifen Xu (Beijing, CN); Hongjun Wang (Beijing, CN); Li Mao (Beijing, CN); Jingtao Li (Beijing, CN); Honglei Zhang (Beijing, CN); Chuangchuang Huang (Beijing, CN); Jing Li (Beijing, CN); Jing Zhao (Beijing, CN); Weina Liu (Beijing, CN); Nana Tian (Beijing, CN); Liying Zhou (Beijing, CN); Yanan Liu (Beijing, CN)

Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.

C07D413/14 A61P15/08 A61P35/00 A61P35/02 C07D405/14 C07D471/04

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12692257
App. No.: 17/926,533
Granted: Jul 28, 2026
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided are compounds represented by general formula (I), which can be used for treating ATR kinase-mediated diseases, such as proliferative diseases, such as cancer. Further provided are a pharmaceutical composition of the compound represented by general formula (I), a use thereof in treating ATR kinase-mediated diseases, and a preparation thereof.

Claims (270)

1 . A compound of general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof:

wherein

X is CR X or N;

Y is CR Y or N;

R 1 , R 2 , R 3 , R 4 and R Y are independently selected from H, D, halogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, or R 1 and R 2 , R 3 and R 4 are connected to form bond, C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene; wherein the groups may be substituted by one or more D or halogens up to fully substituted;

wherein R X is H, D, halogen, —CN, —NRR′, —OR, —SR or C 1-6 alkyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

when Y is CR Y , R Y and R 1 are taken together with the atoms to which they are attached to form C3-5 cycloalkyl or 3- to 5-membered heterocyclyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

ring A is phenyl or 5- to 6-membered heteroaryl;

R a is independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl or 3- to 8-membered heterocyclyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

m is 0, 1, 2, 3, 4 or 5;

ring B is 5- to 10-membered heteroaryl;

R b is independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl or 3- to 8-membered heterocyclyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

n is 0, 1, 2, 3, 4 or 5;

R 5 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 6 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R* is H, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 3-7 cycloalkyl, 3- to 8-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R and R′ are independently selected from H, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, or R and R′ are taken together with the nitrogen atom to which they are attached to form 4- to 8-membered heterocyclyl; wherein the groups may be substituted by one or more D or halogens up to fully substituted;

p is 1 or 2.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof,

wherein R 1 is C 1-6 alkyl, alternatively (R)—C 1-6 alkyl, still alternatively (R)-methyl;

and/or wherein ring A is selected from the following groups:

wherein A 1 is CR a1 or N; A 2 is CR a2 or N; A 3 is CR a3 or N; A 4 is CR a4 or N; A 5 is CR a5 or N;

R a1 , R a2 , R a3 , R a4 and R a5 have the same definition as R a in claim 1 ;

alternatively, ring A is selected from the following groups:

and/or wherein ring B is selected from bicyclic 9- to 10-membered heteroaryl; alternatively, ring B is selected from the following groups:

wherein 0, 1, 2 or 3 of B 1 -B 12 are heteroatoms selected from O, S and N, as long as chemically permissible; and B 1 -B 12 are optionally oxidized to form ═O group; alternatively, at least one of B 1 -B 12 is a heteroatom selected from O, S and N, as long as chemically permissible;

alternatively, 0, 1, 2 or 3 of B 1 -B 12 are a N atom; alternatively, at least one of B 1 -B 12 is a N atom; alternatively, at most one of B 1 -B 3 is a N atom; alternatively, at most two of B 4 -B 6 are a N atom; alternatively, B 4 is a N atom;

alternatively,

B 1 is CR b1 or N; B 2 is CR b2 or N; B 3 is CR b3 or N; B 4 is CR b4 or N; B 5 is CR b5 or N; B 6 is CR b6 or N; B 7 is CR b7 or N; B 8 is CR b8 or N; B 9 is CR b9 or N; B 10 is CR b10 or N; B 11 is CR b11 or N; B 12 is CR b12 or N;

R b1 to R b12 and R b have the same definition as R b in claim 1 ;

n is 0, 1, 2, 3 or 4;

R 7 and R 8 are independently selected from H, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with r R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

wherein R* is H, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 3-7 cycloalkyl, 3- to 8-membered heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

r is 0, 1, 2, 3, 4 or 5;

alternatively, R 7 and R 8 are taken together with the N atom to which they are attached to form 4- to 8-membered heterocyclyl, which may be substituted by one or more D or halogens up to fully substituted;

p is 1 or 2;

alternatively, ring B is selected from the following groups:

still alternatively, ring B is selected from

and/or wherein R a is independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D up to fully deuterated;

and/or wherein R b is independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl or C 1-6 haloalkyl, each of which is optionally substituted with R* group.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, which has the following general structures:

wherein each group has the same definition as claim 1 .

4 . The compound of claim 3 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, which is a compound of general formula (V-1) or (VI-1):

wherein

A 1 is CR a1 or N;

A 2 is CR a2 or N;

A 3 is CR a3 or N;

A 4 is CR a4 or N;

A 5 is CR a5 or N;

R a1 , R a2 , R a3 , R a4 and R a5 are independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl or 3- to 6-membered heterocyclyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b is independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

n is 0, 1, 2, 3 or 4;

R 1 is H, D, halogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 5 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 6 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 7 and R 8 are independently H, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with r R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

r is 0, 1, 2, 3, 4 or 5;

p is 1 or 2.

5 . The compound of general formula (V-1) or (VI-1) of claim 4 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein R a1 , R a2 , R a3 , R a4 and R a5 are independently H, D, halogen, —C(O)OR, —C(O)NRR′, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, which may be substituted by one or more D or halogens up to fully substituted.

6 . The compound of general formula (V-1) or (VI-1) of claim 4 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

A 1 is CR a1 ;

A 2 is CR a2 or N;

A 3 is CR a3 or N;

A 4 is CR a4 or N;

A 5 is CR a5 ;

R a1 , R a2 , R a3 , R a4 and R a5 are independently selected from H, D, halogen, —C(O)OR, —C(O)NRR′, —CN, —NRR′ or —OH, each of which is optionally substituted with R* group;

R b is H, D, halogen, —CN, —NRR′, —OR or —SR;

n is 0, 1, 2, 3 or 4;

R 1 is H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 5 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 6 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 7 and R 8 are independently H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with r R* group, wherein the groups may be substituted by one or more D up to fully deuterated;

r is 0, 1, 2, 3, 4 or 5;

alternatively, R 7 and R 8 are taken together with the N atom to which they are attached to form 4- to 8-membered heterocyclyl, which may be substituted by one or more D up to fully deuterated;

R and R′ are independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, or R and R′ are taken together with the nitrogen atom to which they are attached to form 4- to 8-membered heterocyclyl; wherein the groups may be substituted by one or more D up to fully deuterated;

p is 1 or 2.

7 . The compound of general formula (V-1) or (VI-1) of claim 6 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

R a1 , R a4 and R a5 are independently H or D;

R a2 and R a are independently H, D, halogen, —C(O)OR, —C(O)NRR′, —CN, —NRR′ or —OH;

R 1 is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 5 is H, D, halogen, —CN, C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 6 is H, D, halogen, —CN, C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 7 and R 8 are independently H, C 1-6 alkyl or C 1-6 haloalkyl, each of which is optionally substituted with r R* group, wherein the groups may be substituted by one or more D up to fully deuterated;

R* is H, halogen, —CN, —NRR′, —OR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′ or —NRC(O)NRR′;

r is 0, 1, 2, 3, 4 or 5;

alternatively, R 7 and R 8 are taken together with the N atom to which they are attached to form 4- to 8-membered heterocyclyl, which may be substituted by one or more D up to fully deuterated;

R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl, or R and R′ are taken together with the nitrogen atom to which they are attached to form 4- to 8-membered heterocyclyl; wherein the groups may be substituted by one or more D up to fully deuterated.

8 . The compound of general formula (V-1) or (VI-1) of claim 4 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

A 1 is CR a1 ;

A 2 is CR a2 ;

A 3 is CR a3 or N;

A 4 is CR a4 or N;

A 5 is CR a5 ;

R a1 , R a2 , R a3 , R a4 and R a5 are independently H, D, halogen, —C(O)OH, C(O)NH 2 or —OH;

R b is H, D, halogen or —CN;

n is 0, 1, 2, 3 or 4;

R 1 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 5 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R* is H, halogen, —CN, —NRR′ or —OR;

r is 0, 1, 2, 3, 4 or 5;

alternatively, R 7 and R 8 are taken together with the N atom to which they are attached to form a 4- to 8-membered heterocyclyl;

R and R′ are independently selected from H, C 1-6 alkyl and C 1-6 haloalkyl, or R and R′ are taken together with the nitrogen atom to which they are attached to form 4- to 8-membered heterocyclyl, wherein the groups may be substituted by one or more D up to fully deuterated.

9 . The compound of general formula (V-1) or (VI-1) of claim 8 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

R a1 , R a4 and R a5 are H or D;

R a2 and R a3 are H, D, halogen, C(O)NH 2 or —OH;

R 1 is C 1-6 alkyl or C 1-6 haloalkyl; alternatively methyl;

R 5 is C 1-6 alkyl or C 1-6 haloalkyl; alternatively methyl or —CF 3 ;

R 6 is C 1-6 alkyl or C 1-6 haloalkyl; alternatively methyl or —CF 3 ;

R 7 and R 8 are independently H, C 1-6 alkyl or C 1-6 haloalkyl;

10 . The compound of claim 3 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, which is a compound of general formula (V-2):

wherein

A 1 is CR a1 or N;

A 2 is CR a2 ;

A 3 is CR a3 or N;

A 4 is N;

A 5 is CR a5 or N;

B 2 is CR b2 ;

B 3 is CR b3 ;

R a1 , R a2 , R a3 and R a5 are independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl or 3- to 6-membered heterocyclyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b2 and R b3 are independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b is selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl or 3- to 8-membered heterocyclyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

n is 0, 1, 2, 3 or 4;

R 1 is H, D, halogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 5 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 6 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

p is 1 or 2.

11 . The compound of general formula (V-2) of claim 10 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof,

wherein

A 1 is CR a1 or N;

A 2 is CR a2 ;

A 3 is CR a3 or N;

A 4 is N;

A 5 is CR a5 or N;

B 2 is CR b2 ;

B 3 is CR b3 ;

R a1 , R a2 , R a3 and R a5 are independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b2 and R b3 are independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b is selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

n is 0, 1, 2, 3 or 4;

R 1 is halogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 5 is halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 6 is halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

p is 1 or 2;

alternatively, wherein

A 1 is CR a1 or N;

A 2 is CR a2 ;

A 3 is CR a3 or N;

A 4 is N;

A 5 is CR a5 or N;

B 2 is CR b2 ;

B 3 is CR b3 ;

R a1 is H, D, halogen or —CN;

R a2 is selected from H, D, halogen, —NRR′, —OR, —SR, —C(O)R, —C(O)OR or —C(O)NRR′, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D up to fully deuterated;

R a3 is selected from H, D, halogen, —CN, —NH 2 , —OH, —SH, —C(O)R, —C(O)OR or —C(O)NRR′, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R a5 is selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b2 is selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b3 is selected from H, D, halogen, —CN, —NRR′, —OR or —SR, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b is H, D, halogen or —CN;

n is 0, 1, 2, 3 or 4;

R 1 is halogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 5 is halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 6 is halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R* is H, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR or —C(O)NRR′, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

alternatively, wherein

A 1 is CR a1 or N;

A 2 is CR a2 ;

A 3 is CR a3 or N;

A 4 is N;

A 5 is CR a5 or N;

B 2 is CR b2 ;

B 3 is CR b3 ;

R a1 is H or D;

R a2 is selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR or —C(O)NRR′, each of which is optionally substituted with R* group;

R a3 is selected from H, D, halogen, —CN, —NRR′, —OR, —SR;

R a5 is selected from H, D, halogen, —CN or C 1-6 alkyl, each of which is optionally substituted with R* group;

R b2 is selected from H, D, halogen, —CN or C 1-6 alkyl, each of which is optionally substituted with R* group;

R b3 is selected from H or D, each of which is optionally substituted with R* group;

R b is H or D;

n is 0, 1, 2, 3 or 4;

R 1 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl;

R 5 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl;

R 6 is C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl;

R* is H, halogen, —CN, —NRR′, —OR or —SR;

R and R′ are independently selected from H or C 1-6 alkyl.

12 . The compound of claim 3 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, which is a compound of general formula (V-2) or (VI-2):

wherein

A 1 is CR a1 or N;

A 2 is CR a2 or N;

A 3 is CR a3 or N;

A 4 is CR a4 or N;

A 5 is CR a5 or N;

B 2 is CR b2 or N;

B 3 is CR b3 or N;

R b2 , R b3 and R b are independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)R, —C(O)OR, —C(O)NRR′, —OC(O)R′, —NRC(O)R′, —OC(O)NRR′, —NRC(O)NRR′, —S(O) p R, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

n is 0, 1, 2, 3 or 4;

R 1 is H, D, halogen, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 5 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R 6 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

p is 1 or 2.

13 . The compound of general formula (V-2) or (VI-2) of claim 12 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

R a1 , R a2 , R a3 , R a4 and R a5 are independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, —C(O)OR, —C(O)NRR′, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted;

R b2 , R b3 and R b are independently selected from H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D or halogens up to fully substituted.

14 . The compound of general formula (V-2) or (VI-2) of claim 12 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

A 1 is CR a1 or N;

A 2 is CR a2 or N;

A 3 is CR a3 or N;

A 4 is CR a4 or N;

A 5 is CR a5 or N;

alternatively, at least one of A 3 , A 4 and A 5 is N;

B 2 is CR b2 or N;

B 3 is CR b3 or N;

R a1 , R a2 , R a3 , R a4 and R a5 are H, D, halogen, —CN, —NRR′ or —OH;

R b2 , R b3 and R b are independently selected from H, D, halogen, —CN, —NRR′, —OR, C 1-6 alkyl or C 1-6 haloalkyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D up to fully deuterated;

n is 0, 1, 2, 3 or 4;

R 1 is H, D, halogen, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 5 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 6 is H, D, halogen, —CN, —NRR′, —OR, —SR, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R* is H, halogen, —CN, —NRR′, —OR or —SR;

15 . The compound of general formula (V-2) or (VI-2) of claim 14 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

R b2 , R b3 and R b are independently selected from H, D, halogen, —CN, —NRR′, —OH, C 1-6 alkyl or C 1-6 haloalkyl, each of which is optionally substituted with R* group, wherein the groups may be substituted by one or more D up to fully deuterated;

R 1 is H, D, halogen, C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 5 is H, D, halogen, —CN, C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 6 is H, D, halogen, —CN, C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated.

16 . The compound of general formula (V-2) or (VI-2) of claim 12 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

A 1 is CR a1 or N;

A 2 is CR a2 or N;

A 3 is CR a3 or N;

A 4 is CR a4 or N;

A 5 is CR a5 or N;

alternatively, at least one of A 3 , A 4 and A 5 is N;

B 2 is CR b2 or N;

B 3 is CR b3 or N;

R a1 and R a5 are H or D;

R a3 is H, D or OH;

R a2 and R a4 are H, D, halogen, —NRR′ or —OH;

n is 0, 1, 2, 3 or 4;

R 1 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 5 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R 6 is C 1-6 alkyl or C 1-6 haloalkyl, wherein the groups may be substituted by one or more D up to fully deuterated;

R* is H, halogen, —CN, —NRR′, —OR or —SR;

17 . The compound of general formula (V-2) or (VI-2) of claim 16 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, or a mixture thereof, wherein

R b2 , R b3 and R b are independently selected from H, D, halogen, —CN, C 1-6 alkyl or C 1-6 haloalkyl, each of which is optionally substituted with R* group;

R 1 is C 1-6 alkyl or C 1-6 haloalkyl; alternatively methyl;

R 5 is C 1-6 alkyl or C 1-6 haloalkyl; alternatively methyl or —CF 3 ;

R 6 is C 1-6 alkyl or C 1-6 haloalkyl; alternatively methyl or —CF 3 .

18 . The compound of claim 1 , which is selected from:

19 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, and a pharmaceutically acceptable excipient; alternatively, further comprising other therapeutic agent (s).

20 . A method of treating and/or preventing a disease in a subject, comprising administering to the subject the compound of claim 1 or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof;

wherein the disease is a cancer mediated by ATR kinase.

21 . The method of claim 20 , wherein the cancer comprises breast cancer, colorectal cancer, lung cancer, prostate cancer and bile duct cancer, bone cancer, bladder cancer, head and neck cancer, kidney cancer, liver cancer, gastrointestinal cancer, esophageal cancer, ovarian cancer, pancreatic cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, cervical cancer and vulvar cancer, and leukemia, multiple myeloma and lymphoma.

22 . The method of claim 20 , wherein the cancer comprises breast cancer, colorectal cancer, small cell lung cancer, non-small cell lung cancer, bronchioloalveolar carcinoma, prostate cancer and bile duct cancer, bone cancer, bladder cancer, head and neck cancer, kidney cancer, liver cancer, gastrointestinal cancer, esophageal cancer, ovarian cancer, pancreatic cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, cervical cancer and vulvar cancer, acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), multiple myeloma and lymphoma.